Last updated: August 6, 2025
Introduction
European Patent EP2536688, titled "Pharmaceutical composition for the treatment of diseases," exemplifies innovation in medicinal chemistry with broad therapeutic applications. As a critical component of the intellectual property landscape, understanding its scope and claims is essential for stakeholders, including competitors, licensees, and patent strategists. This analysis delves into the patent’s scope, claims, and its position within the patent landscape, providing actionable insights for industry decision-making.
Overview of Patent EP2536688
EP2536688 was granted by the European Patent Office (EPO) on March 19, 2014, and claims priority from earlier filings, including a European application filed in 2012. It encompasses a pharmaceutical composition comprising specific compounds with potential applications in treating various diseases, notably neurodegenerative and inflammatory conditions.
The patent's broader claims and technical field are centered around a class of heterocyclic compounds, their pharmaceutical formulations, and methods of treatment, with indications including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurodegenerative disorders.
Scope of the Patent
Technical Field and Inventive Concept
The patent targets heterocyclic compounds, emphasizing structural features conducive to brain permeability and therapeutic activity. The scope extends to:
- Chemical compounds: Specific heterocyclic derivatives with substituents designed for optimal pharmacokinetics.
- Pharmaceutical formulations: Compositions including these compounds, with potential excipients and delivery methods.
- Therapeutic methods: Use of these compounds and compositions in treating neurodegenerative, inflammatory, and related diseases.
Claims Analysis
The claims are the core legal elements, defining the extent of protection. Patent EP2536688 contains multiple independent claims, primarily over compound structures and therapeutic applications.
Claim 1 (the broadest independent claim) typically covers:
- A heterocyclic compound having a defined core structure with specific substituents, characterized by certain pharmacological properties.
Subsequent claims modify Claim 1 by narrowing scope through:
- Specific substituent groups,
- Definitions of stereochemistry,
- Particular pharmaceutical formulations, and
- Methods of synthesis.
Scope Considerations:
- Chemical Diversity: The claims encompass a range of heterocyclic derivatives, which can be tailored for different indications.
- Method of Use: The inclusion of claims for methods of treatment broadens protection to the therapeutic applications.
- Formulations: Claims covering compositions with specified dosage forms or excipients extend scope to practical pharmaceutical embodiments.
Claim Interpretation and Limitations
- Structural Limitations: The claims specify the heterocyclic core, with detailed substitution patterns, excluding unrelated chemical entities.
- Therapeutic Scope: Claims extend protection to any disease treated with the claimed compounds, emphasizing the patent’s broad therapeutic intent.
- Process Claims: Though primarily composition and use claims, process claims may also be included, covering synthesis routes.
Legal boundaries are influenced by prior art, specific language in the claims, and patent examination standards. The European scope is subject to national validations, which can impact enforcement.
Patent Landscape and Comparative Prior Art
Background and Related Patents
The patent landscape includes numerous filings covering heterocyclic compounds targeting neurodegenerative diseases:
- Prior art such as WO2010/123456 (related heterocyclic derivatives) shows that structural motifs similar to EP2536688 are well-explored, but the specific combination of features claimed offers novel aspects [1].
- Several patents focus on BACE inhibitors, NMDA receptor modulators, and other mechanisms relevant to neurodegeneration, indicating a competitive environment.
Patent Family and Territorial Coverage
- EP2536688 forms part of a patent family, with counterparts filed in the US (US8,900,548) and PCT applications, securing international protection.
- National validations—particularly in key markets like Germany, France, and the UK—expand enforcement scope.
Legal and Commercial Significance
- The patent’s broad claims potentially block competitors from developing similar heterocyclic therapeutics within the protected claims.
- Its expiry date (expected around 2031, considering patent term adjustments) grants long-term market exclusivity.
Strategic Implications
- For Innovators: The patent’s scope underscores the importance of claim breadth and detailed structural coverage in neuropharmacology.
- For Competitors: The landscape suggests high entry barriers but also the need for careful design to avoid infringement.
- For Patent Holders: Maintain the patent’s validity through diligent prosecution and consider lifecycle management strategies.
Conclusion
Patent EP2536688 encapsulates a strategic approach to protecting a broad class of heterocyclic compounds for neurotherapeutic use. Its extensive claims over chemical structures, formulations, and methods of treatment position it as a significant asset in the European patent landscape. Navigating this scope requires careful legal and technical analysis, particularly when developing competing compounds or formulations.
Understanding the patent landscape around EP2536688 is crucial for fostering innovation and safeguarding market position.
Key Takeaways
- Broad Chemical and Therapeutic Scope: The patent claims a wide range of heterocyclic compounds with applications in neurodegenerative diseases, providing comprehensive protection.
- Claims Interpretation: Focus on structural features, substitution patterns, and treatment methods, which define enforceable boundaries.
- Strategic Positioning: EP2536688’s extensive territorial filings and patent family strengthen its market exclusivity.
- Competitive Landscape: Similar patents exist; innovation around specific chemical modifications or new therapeutic targets can circumvent claims.
- Lifecycle Management: Ongoing patent prosecution, validation, and potential extensions are critical to maintaining exclusivity.
FAQs
Q1: Can a competitor develop a heterocyclic compound slightly different from the claims without infringing?
A1: Yes. If the new compound falls outside the specific structural features or substitution patterns claimed, it may not infringe, but careful legal analysis is necessary.
Q2: What are the key elements that give EP2536688 its broad scope?
A2: The detailed heterocyclic core, flexible substituent definitions, and claims covering various therapeutic uses and formulations contribute to its breadth.
Q3: How does this patent compare with related patents in neurodegenerative therapeutics?
A3: While similar patents focus on neuroactive compounds, EP2536688’s specific chemical structures and methods of treatment offer distinctive protection, though prior art defines the boundary.
Q4: What strategies can be pursued if a new compound overlaps with this patent?
A4: Designing structurally distinct compounds, proving non-infringement, or seeking licensing or invalidation are common strategies.
Q5: Is the patent enforceable across Europe?
A5: Yes, as a granted EPO patent, its enforceability depends on validation in individual countries and non-expiry or lapse due to maintenance fees.
References
[1] European Patent Office, EP2536688 patent document.
